Cramer honestly believes that regular investors can outperform the broad market every day, including today, simply by following this strategy.» Read More
Dec 17- Pfizer Inc on Tuesday said it would allow Teva Pharmaceutical Industries to sell generic forms of its Viagra anti-impotence treatment in the United States beginning in late 2017, in a settlement of longstanding patent litigation between the two drugmakers.
Dec 16- Valeant Pharmaceuticals International Inc, which agreed on Monday to buy Solta Medical Inc, is one of Canada's fastest-rising stocks.
The FDA said it approved cheaper versions of the drug, known chemically as duloxetine, in a variety of strengths for sale by several generic drugmakers, including Teva Pharmaceutical Industries Ltd, Aurobindo Pharma Ltd, Dr. Reddy's Laboratories Ltd, Lupin Ltd, Sun Pharmaceutical Industries and Torrent Pharmaceuticals Ltd..
TEL AVIV, Dec 8- Teva Pharmaceutical Industries, the world's biggest maker of generic drugs, estimates its pipeline of so-called new therapeutic entities could generate revenue of $1 billion to $1.5 billion by 2018..
WASHINGTON, Nov 13- A U.S. Supreme Court justice on Wednesday declined a request from Teva Pharmaceutical Industries for a stay of an appeals court ruling that would strip the company's $4 billion- a-year multiple sclerosis drug Copaxone of patent protection in 2014, rather than in 2015..
Oct 31- Valeant Pharmaceuticals International Inc, Canada's biggest publicly traded drugmaker, posted a quarterly net loss on Thursday after restructuring and impairment charges, and cut its full-year revenue outlook.
Take a look at some of Wednesday's midday movers:
TEL AVIV, Oct xx- High-tech entrepreneur Eyal Waldman decided he had had enough of Israeli investors when they told him to choose between his titles of chairman and chief executive at the company he co-founded, Mellanox Technologies. "Mellanox is not an impulsive company. is something we were thinking of, that we saw build up.
TEL AVIV, Oct 30- Teva Pharmaceutical Industries, the world's largest generic drugmaker, said its chief executive Jeremy Levin was stepping down and finance chief Eyal Desheh would stand in on an interim basis, effective immediately.
Take a look at some of Monday's midday movers:
JERUSALEM, Oct 28- Teva Pharmaceutical Industries and Chief Executive Jeremy Levin denied an Israeli media report that Levin was considering resigning due to a rift with the company's board of directors.
Channel 2 television quoted unnamed sources as saying there were strong differences of opinion between Levin and Chairman Phillip Frost over the implementation of Teva's new strategy.
GlaxoSmithKline's pharmaceutical and vaccine sales to China tumbled 61 percent in the third quarter, with the drugmaker hit by an ongoing bribery investigation.
*Sees 2013 revenue near midpoint of $19.5- $20.5 bln estimate. JERUSALEM, Oct 10- Teva Pharmaceutical Industries will cut about 5,000 jobs, 10 percent of its workforce, accelerating a cost-cutting plan as it prepares for lower-priced competition for its best-selling drug.
Oct 4- Biogen Idec's hot-selling new multiple sclerosis drug Tecfidera remained effective for patients taking the medicine for at least four years with no new safety problems, according to interim data from a long-term study.
The economy may have added as many as 200,000 jobs in July amid the backdrop of a pickup in manufacturing activity and fewer layoffs.
Check out which companies are making headlines after the bell Thursday:
Traders are looking past ISM manufacturing data and weekly jobless claims, to the July nonfarm payrolls because it will be key in the Fed's decision making process.
It’s time for the Lightning Round. Cramer makes the call on viewer favorites.
The "Fast Money" traders share their final trades of the day.